Jump to content

Moshe Szyf

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by David.ch (talk | contribs) at 15:24, 11 January 2017 (→‎External links). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Moshe Szyf
Scientific career
FieldsEpigenetics and Cancer research

Moshe Szyf is a geneticist and James McGill professor of pharmacology and therapeutics at the McGill University, where he also holds a GlaxoSmithKline-CIHR chair in pharmacology. He is one of the pioneers of epigenetics.

Szyf's main research interests lie with epigenetics, including behavioral epigenetics as well as cancer research.

Education and career

Szyf received his Ph.D. from the Hebrew University on basic mechanisms of DNA methylation under supervision of Aharon Razin. Subsequently he performed postdoctoral work at Harvard Medical School. In 1989, he was appointed as assistant professor in pharmacology and therapeutics at McGill University.[1] In 2016, Moshe Szyf founded Montreal EpiTerapia Inc.

Publications

Books
  • Moshe Szyf, DNA Methylation and Cancer Therapy, Springer, 2005, ISBN 978-0306478482
  • Moshe Szyf, Fundamentals of Epigenetics, Cambridge University Press, ISBN 978-0521898379
Articles

As of October 2013, Moshe Szyf published more than 140 papers in peer-reviewed journals, almost all on epigenetics.[2] He is also on the Editorial Board of the journal Environmental Epigenetics, published by Oxford University Press.[3]

Szyf also holds many patents, all relating to epigenetics-based therapeutics.[2]

References

  1. ^ Dr. Moshe Szyf, 6th International Conference on Genomics (ICG), 2011
  2. ^ a b Moshe Szyf, sickkids.ca
  3. ^ "Environmental Epigenetics Editorial Board". Environmental Epigenetics Editorial Board. Retrieved 17 April 2015.

External links